Motion correction in PET/CT

2005 ◽  
Vol 44 (S 01) ◽  
pp. S46-S50 ◽  
Author(s):  
M. Dawood ◽  
N. Lang ◽  
F. Büther ◽  
M. Schäfers ◽  
O. Schober ◽  
...  
Keyword(s):  
Optical Flow ◽  
Motion Correction ◽  
Motion Vector ◽  
Emission Tomography ◽  
Cardiac Pet ◽  
Novel Approach ◽  
Positron Emission ◽  
Pet Ct ◽  
Flow Algorithm ◽  
Motion Vector Field

Summary:Motion in PET/CT leads to artifacts in the reconstructed PET images due to the different acquisition times of positron emission tomography and computed tomography. The effect of motion on cardiac PET/CT images is evaluated in this study and a novel approach for motion correction based on optical flow methods is outlined. The Lukas-Kanade optical flow algorithm is used to calculate the motion vector field on both simulated phantom data as well as measured human PET data. The motion of the myocardium is corrected by non-linear registration techniques and results are compared to uncorrected images.

scholarly journals Motion Correction in Respiratory Gated Cardiac PET/CT Using Multi-scale Optical Flow

2008 ◽  
pp. 155-162 ◽  
Author(s):  
Mohammad Dawood ◽  
Thomas Kösters ◽  
Michael Fieseler ◽  
Florian Büther ◽  
Xiaoyi Jiang ◽  
...  
Keyword(s):  
Optical Flow ◽  
Motion Correction ◽  
Cardiac Pet ◽  
Multi Scale ◽  
Pet Ct

scholarly journals PET-CT Sarcoidosis-A Brief Review and Consideration For PET-CT Patient Workflow.

2020 ◽  
pp. 1-6
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Field ◽  
Computed Tomography ◽  
Cardiac Sarcoidosis ◽  
Emission Tomography ◽  
Cardiac Pet ◽  
Resonance Imaging ◽  
Positron Emission ◽  
Pet Ct ◽  
Treatment Considerations

Cardiovascular disease continues to lead as one of the greatest contributors to mortality [1]. Cardiac sarcoidosis is a lesser known but highly lethal clinical condition that has been increasing in incidence and prevalence globally [1]. Within the radiologic modalities, both cardiac magnetic resonance imaging (MR) and positron emission tomography-computed tomography (PET-CT) have emerged as ideal imaging modalities used in evaluating and assisting with treatment considerations for cardiac sarcoidosis. MR and PET-CT are complementary in regards to imaging capabilities but certain patient population considerations lend themselves to favoring PET-CT over MR, In particular, although an increasing number of implanted cardiac defibrillators (ICDs) are MR-compatible, many patients do not have MR-compliant devices and are unable to have MR for sarcoidosis evaluation due to the dangers inherent to the MR’s magnetic field and the ferromagnetic properties of ICDs. For patient safety, cardiac PET-CT may be the only effective imaging option available.

The Potential Value of Hybrid Positron Emission Tomography/Dual-Source Computed Tomography Imaging in Coronary Bypass Surgery

2011 ◽  
Vol 14 (5) ◽  
pp. 283 ◽  
Author(s):  
Andre Plass ◽  
Maximilian Y. Emmert ◽  
Oliver Gaemperli ◽  
Hatem Alkadhi ◽  
Philipp Kaufmann ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Coronary Artery ◽  
Coronary Angiography ◽  
Myocardial Perfusion ◽  
Predictive Value ◽  
Bypass Surgery ◽  
Emission Tomography ◽  
Positron Emission ◽  
Pet Ct

<p><b>Background:</b> We evaluated how comprehensive assessment of coronary artery lesions and their hemodynamic relevance by means of hybrid positron emission tomography (PET) and computed tomography (CT) imaging would affect decision-making in coronary artery bypass surgery (CABG), compared with using invasive coronary angiography (ICA) alone.</p><p><b>Methods:</b> After undergoing ICA, 27 patients (21 men and 6 women; mean SD age, 66 � 10 years) planned for cardiac surgery were scheduled for myocardial perfusion stress/rest evaluation with [13N]ammonia PET and CT coronary angiography. Only ICA was available to the surgeon. Postoperatively, the performed CABG was compared with the hypothetical strategy based on hybrid PET/CT findings (regional coronary flow reserve [CFR], myocardial perfusion defects). Procedures included CABG (n = 18) alone, CABG combined with valve replacement (n = 6), and CABG combined with isolated valve replacement (n = 3). A total of 56 bypass grafts (28 venous and 28 arterial) and 66 distal anastomoses were placed.</p><p><b>Results:</b> CT evaluation showed 93% concordance (66/71) with ICA regarding significant stenoses, with sensitivity, specificity, positive predictive value, and negative predictive value of 93.1%, 98.7%, 94.4%, and 98.4%, respectively. In the PET scan, 16 patients had 1 ischemic region, and 12 patients had 1 scar region, including 5 patients who presented with mixed conditions (scar and ischemia). One patient had a completely normal myocardium. Compared with the performed surgery, PET/CT fusion evaluation showed that of the performed anastomoses, 48% had documented ischemia (with a CFR <2 in 86%), 38% were nonischemic (although a CFR value <2 was found in 78%), and 14% had scar tissue (fixed perfusion defect).</p><p><b>Conclusions:</b> Although <50% of bypasses were placed to areas with myocardial ischemia, the CFR was low in the majority of nonischemic regions, a finding that may have important prognostic relevance. PET/CT fusion imaging could potentially influence planning for CABG and provide incremental prognostic information.</p>

Integrating PET/CT unit into the NHS of a small sized EU state: A financial cost efficiency study

2020 ◽  
Vol 30 (Supplement_5) ◽  
Author(s):  
K Giannakou ◽  
D Kefallonitou ◽  
I Polycarpou ◽  
K Souliotis
Keyword(s):  
Cost Efficiency ◽  
Financial Analysis ◽  
National Health System ◽  
Emission Tomography ◽  
Alternative Possibilities ◽  
Financial Cost ◽  
Positron Emission ◽  
Pet Ct ◽  
Investment Cost ◽  
Two Alternatives

Abstract Background According to the Ministry of Health in Cyprus, since 2009, every year more than 3.000 new incidents with neoplasm are diagnosed. The National Health System (NHS) of Cyprus aims to offer adequate health services, comparing them with European Union standards. However, it is lacking a Positron Emission Tomography-Computed Tomography (PET/CT) unit. The present study aims to examine whether an investment by the Cyprus NHS of a PET/CT unit can be financially sustainable. Methods A financial analysis of the operating revenues and expenses of a departmental PET/CT with F18-FDG was performed taking into consideration all related parameters. A detailed estimation of the unit's operation expenses (PET/CT unit supply, overheads, salaries, etc.) and incomes was produced for a 15-year period. This initial scenario was not financially viable and therefore two alternatives are also examined. Results After performing a detailed analysis and projection for the evaluation of the feasibility study in the initial scenario, the overall outcome is estimated negative deriving to a €2,2 million losses in the cumulative results by 2035. The second scenario concluded that the required number of incidents to reach a neutral cash flow after a 15-year period should increase from 8.971 to 23.430. The third scenario reached the conclusion that a parallel investment to the purchase of the PET/CT unit by installing a cyclotron unit in the Cypriot NHS provides cumulative results positive of €1,7 million for the PET/CT, in the same period, that can finance the largest part of the €2,5 million required for the installation of the cyclotron unit. Conclusions Our findings show that an investment of a sole PET/CT unit is not a financially viable. Alternative possibilities such as usage of a PET/CT operated by the private sector or supporting patients to travel to another country are within the economic terms recommended. Key messages From a financial viewpoint, the scenario of investing in a PET/CT unit by the Cyprus NHS is not viable. Examining alternative options for patients in need of a PET/CT unit, where the initial investment cost for the state is not financially viable.

Influence of Baseline Positron Emission Tomography in Metastatic Gastroesophageal Cancer on Survival and Response to Therapy

Oncology ◽  
2021 ◽  
pp. 1-6
Author(s):  
Ahmed Abdelhakeem ◽  
Madhavi Patnana ◽  
Xuemei Wang ◽  
Jane E. Rogers ◽  
Mariela Blum Murphy ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Response To Therapy ◽  
Emission Tomography ◽  
Gastroesophageal Cancer ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy ◽  
Positron Emission ◽  
Pet Ct ◽  
Metastatic Burden

<b><i>Background:</i></b> The value of baseline fluorodeoxyglucose-positron emission tomography-computed tomography (PET-CT) remains uncertain once gastroesophageal cancer is metastatic. We hypothesized that assessment of detailed PET-CT parameters (maximum standardized uptake value [SUVmax] and/or total lesion glycolysis [TLG]), and the extent of metastatic burden could aid prediction of probability of response or prognosticate. <b><i>Methods:</i></b> We retrospectively analyzed treatment-naive patients with stage 4 gastroesophageal cancer (December 2002–August 2017) who had initial PET-CT for cancer staging at MD Anderson Cancer Center. SUVmax and TLG were compared with treatment outcomes for the full cohort and subgroups based on metastatic burden (≤2 or &#x3e;2 metastatic sites). <b><i>Results:</i></b> We identified 129 patients with metastatic gastroesophageal cancer who underwent PET-CT before first-line therapy. The median follow-up time was 61 months. The median overall survival (OS) was 18.5 months; the first progression-free survival (PFS) was 5.5 months. SUVmax or TLG of the primary tumor or of all metastases combined had no influence on OS or PFS, whether the number of metastases was ≤2 or &#x3e;2. Overall response rates (ORRs) to first-line therapy were 48% and 45% for patients with ≤2 and &#x3e;2 metastases, respectively (nonsignificant). ORR did not differ based on low or high values of SUVmax or TLG. <b><i>Conclusions:</i></b> This is the first assessment of a unique set of PET-CT data and its association with outcomes in metastatic gastroesophageal cancer. In our large cohort of patients, detailed analyses of PET-CT (by SUVmax and/or TLG) did not discriminate any parameters examined. Thus, baseline PET-CT in untreated metastatic gastroesophageal cancer patients has limited or no utility.

Sign in / Sign up

Export Citation Format

Share Document